Tyrosine kinase inhibitors (TKI) are employed to attack specific types of cancer cells. The downside to using TKs is that they can cause serious inflammation. A team of researchers has discovered the ...
Neoadjuvant TKI therapy in non-metastatic GIST patients can reduce surgical complexity, with CE-CT imaging predicting benefits in 22 of 39 patients. Significant tumor volume reduction was observed ...
Preoperative VEGFR-TKI plus ICI therapy in advanced ccRCC normalizes tumor vasculature, enhances CD8⁺ T/B cell infiltration, and promotes TLS maturation, leading to profound tumor microenvironment ...
A real-world study demonstrated better survival outcomes when an immunotherapy is combined with a tyrosine kinase inhibitor rather than another immunotherapy therapy for intermediate-risk renal cell ...
In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.
LOUISVILLE, Ky. -- Patients with bone-predominant metastatic renal cell carcinoma (RCC) appeared to have better outcomes when they started treatment with a targeted drug, results of a small ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this Healio Video Perspective from the ASRS meeting, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback